Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma

Inclusion Criteria:

* Cytologically or histologically proven Nasopharyngeal Carcinoma(WHO 2003 I-III) .
* Presence of at least one measurable target lesion (RECIST rules) in a non irradiated region;
* age ≥18 years;
* radiation therapy history for histologically confirmed NPC administered≥6 months prior to study entry;
* radiographic evidence to support the diagnosis of RN with out tumor recurrence or metastases;
* patients had never received Antiangiogenic agents for RN treatment prior to the screening;
* patients had never received corticosteroids for RN treatment prior to the screening;
* no evidence of very high intracranial pressure suggestive of a brain hernia requiring surgery routine laboratory studies including urinalysis, complete blood count, liver function, renal function, and coagulation test within a normal range;
* to understand and be willing to sign a written informed consent.

Exclusion Criteria:

* Other types of Nasopharyngeal Carcinoma;
* Recurrent nasopharyngeal carcinoma, resection of encephalopathy, metastasis, hepatitis, other malignant tumors, neurovascular diseases, or other diseases of the nervous system;
* Inadequately controlled diabetes (FBG \> 10mmol/L) and hypertension(systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg);
* Other severe concurrent disorders that occurred before enrollment (severe or unstable angor, NYHA class 3 or 4 congestive heart failure, Myocardial infarction occurred within 6 months before enrollment；Aortic dissection aortic aneurysm.) active central nervous system hemorrhage;
* pregnant or lactating women, women who have not undergone a pregnancy test (within 14 days prior to initial administration), and pregnant women;
* Patients with a history of severe mental illness or communication disorders.